Anticorps Polyclonal de lapin anti-ATP1A3 (C-terminal)

ATP1A3 (C-terminal) Polyclonal Antibody for WB, IHC, IF-P, Indirect ELISA

Hôte / Isotype

Lapin / IgG

Réactivité testée

Humain, rat, souris

Applications

WB, IHC, IF-P, Indirect ELISA

Conjugaison

Non conjugué

N° de cat : 10868-1-PBS

Synonymes

ATP1A3, ATP1A3 (middle), Alpha(III), ATP1A 3, DYT12



Informations sur le produit

10868-1-PBS cible ATP1A3 (C-terminal) dans les applications de WB, IHC, IF-P, Indirect ELISA et montre une réactivité avec des échantillons Humain, rat, souris

Réactivité Humain, rat, souris
Hôte / Isotype Lapin / IgG
Clonalité Polyclonal
Type Anticorps
Immunogène ATP1A3 (C-terminal) Protéine recombinante Ag1313
Nom complet ATPase, Na+/K+ transporting, alpha 3 polypeptide
Masse moléculaire calculée 113 kDa
Poids moléculaire observé 100-113 kDa
Numéro d’acquisition GenBankBC015566
Symbole du gène ATP1A3
Identification du gène (NCBI) 478
Conjugaison Non conjugué
Forme Liquide
Méthode de purification Purification par affinité contre l'antigène
Tampon de stockage PBS only
Conditions de stockageStore at -80°C. 20ul contiennent 0,1% de BSA.

Informations générales

ATP1A3 participates in the catalyticing hydrolysis of ATP and the exchanging of sodium and potassium ions across plasma membrane. The catalyticing activity mode is ATP + H2O + Na+(In) + K+(Out) = ADP + phosphate + Na+(Out) + K+(In). It has been published that the neurologic disorders rapid-onset dystonia-parkionsonism (RDP), alternating hemiplegia of childhood (ACH) and CAPOS syndrome (cerebellar ataxia, areflexia, pes cavus, optic atrophy and sensorineural hearing loss) are all related with the mutation of ATP1A3. There are other reports suggest that early life epilepsy and episodic apnea revealing are potentially associated with the mutation of ATP1A3 as a result of impairment of Na+/K+ homeostasis. This antibody is generated against the C-terminal region (665-1013aa) of ATP1A3 and detects the band around 100-113 kDa in SDS-PAGE.(PMID: 30097153, 20301294, 29922587)

{{ptg:RelatedPrimaryAntibodies}}